Penny stock picks | research with support and resistance for trading | stock investing
day investing picks penny stock trading
Skip Navigation Links
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event

Join Now

Advertise 2 my advertising 3 of 5

NEKTAR THERAPEUTICS COM support, resistance research

Stock : NKTR |   Stock Recommendations : Buy
Sector : Medical Equipment & Supplies |   First resistance : 7.26
Stock Name : NEKTAR THERAPEUTICS COM |   Second resistance : 13.15
Buy Near : 5.53 |   Third resistance : 17.00
StopLoss : 3.64 |   First Support : 3.64
Posted date : 11/2/2008 12:00:00 AM |   Second Support : 2.91

Nektar Therapeutics com (NKTR) given a nice double top breakout on 10/31/08 with good volume. Again many technical indicators also have given a buy signal, with

   rising moving average weekly and daily Stockhastic given a buy signal and ADX also given a buy signal. Nektar Therapeutics com (NKTR) reported positive Phase 1 data for its lead proprietary oncology product candidate, NKTR-102. As per technical indicator analysis this Stock looks good candidate for portfolio investment and also for day trading, Stock investing, trend trading | swing trading. Due to Stock market and economic condition keep tight stop loss on all position. Buy with our first target $7.26 and keep stop loss $3.64

Penny Stocks

Recent News Head Lines
Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track
(Fri, 26 Feb 2021 14:09:02 +0000)
Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.
Need To Know: The Consensus Just Cut Its Nektar Therapeutics (NASDAQ:NKTR) Estimates For 2021
(Fri, 26 Feb 2021 12:20:48 +0000)
The analysts covering Nektar Therapeutics ( NASDAQ:NKTR ) delivered a dose of negativity to shareholders today, by...
Nektar Posts Better-Than-Feared Quarterly Loss, Misses On Revenues
(Fri, 26 Feb 2021 08:11:58 +0000)
Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts’ expectations for revenues. Shares of the biopharmaceutical company dropped almost 1.5% to close at $22.44 on Feb. 25. Nektar (NKTR) incurred a loss of $0.65 per share in 4Q, compared to the $0.68 loss per share estimated by analysts. Total sales generated in the quarter amounted to $23.5 million, falling short of analysts’ expectations of $30.01 million. The company’s research and development expenses were $102.7 million in the quarter, down 7% year-over-year. (See Nektar stock analysis on TipRanks) Nektar CEO Howard W. Robin said, “This past year, Nektar made significant progress advancing our clinical pipeline of novel cytokine therapeutics.” “For our PROPEL study, we look forward to reporting the first data for BEMPEG plus pembrolizumab in patients with metastatic non-small cell lung cancer in the second half of 2021,” Robin added. On Feb.17, Nektar entered into an agreement with Merck (MRK), a pharmaceutical company, for a Phase 2/3 study of IL-2 pathway agonist, bempegaldesleukin, in combination with Merck’s KEYTRUDA (pembrolizumab) in patients suffering from squamous cell carcinoma of the head and neck (SCCHN). The study is likely to begin in the second half of 2021. On Feb. 18, Mizuho Securities analyst Difei Yang maintained a Buy rating and a price target of $35 (56% upside potential) on the stock as the analyst doesn’t “see significant upside from the deal relative to potential future milestone payments.” Yang expects “upcoming Phase 1/2 data in NSCLC and initial Phase 3 ORR data in melanoma as the key value drivers for NKTR shares in 2H21.” The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating. That’s based on 3 Buys and 3 Holds. The average analyst price target of $28.60 implies more than 27% upside potential to current levels. Shares have jumped 32% so far this year. Nektar scores a 9 out of 10 from TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations. Related News: Analog Devices Posts Better-Than-Expected 1Q Earnings Amid Strong Chip Demand Moody’s Posts Better-Than-Expected 4Q Revenue But Profit Disappoints Lincoln Electric Posts Better-Than-Expected Quarterly Profit; Street Sees 5% Upside More recent articles from Smarter Analyst: Tandem Diabetes Surpasses 4Q Estimates; Shares Rise 4% Beyond Meat Posts Mixed 4Q Results; Street Says Hold Merck Inks Deal To Buy Pandion Therapeutics For $1.85B; Shares Skyrocket Domino’s 4Q Results Miss Analysts’ Expectations; Shares Tank 7%
Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript
(Fri, 26 Feb 2021 06:01:12 +0000)
Ladies and gentlemen, thank you for standing by, and welcome to the Nektar Therapeutics Fourth Quarter 2020 Financial Results. With us on the call are Howard Robin, our President and CEO; Gil Labrucherie, our COO and CFO; Dr. Jonathan Zalevsky, our Chief of Research and Development; and Dr. Brian Kotzin, our Interim Chief Medical Officer and Head of Development.
Nektar Therapeutics: Q4 Earnings Insights
(Thu, 25 Feb 2021 22:10:09 +0000)
Shares of Nektar Therapeutics (NASDAQ:NKTR) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 1.56% over the past year to ($0.65), which beat the estimate of ($0.68). Revenue of $23,462,000 declined by 30.71% from the same period last year, which missed the estimate of $30,010,000. Outlook Nektar Therapeutics hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Feb 25, 2021 View more earnings on NKTR Time: 05:00 PM ET Webcast URL: Recent Stock Performance 52-week high: $26.75 52-week low: $13.63 Price action over last quarter: Up 30.88% Company Overview Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo. See more from BenzingaClick here for options trades from BenzingaBenzinga's Top Ratings Upgrades, Downgrades For February 22, 2021© 2021 Benzinga does not provide investment advice. All rights reserved.

Never go against major trend for Penny stock trading | investing

Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006
Chart courtesy of
Penny stock trading- NEKTAR THERAPEUTICS COM for penny stock investing Day Trading

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.